Summary of Sarepta Therapeutics FY Conference Call Company Overview - **Company**: Sarepta Therapeutics (NasdaqGS:SRPT) - **Event**: FY Conference Call on March 03, 2026 Key Points Financial Guidance - Sarepta guided to 2026 net product revenue of **$1.2 billion to $1.4 billion**, with a comfortable consensus estimate of **$900 million** for PMO revenue, implying **$300 million to $500 million** for ELEVIDYS revenue [1][2][3] Product Dynamics - The company emphasized the difference between one-time therapies and chronically dosed therapies, noting that the revenue from a one-time therapy starts from zero each quarter [2][4] - The turnaround time for patient treatment is approximately **six months**, which affects revenue recognition [2][13] Sales Force Expansion - Sarepta is expanding its sales force, doubling the number of representatives, with a focus on peripheral sites and patient finding [2][30][46] - The first wave of sales representatives has been hired and trained, with a contract sales force also being utilized [2][41][45] Q1 Revenue Expectations - The company anticipates a **15% decline** in Q1 revenue due to factors such as prescription requirements for each child and potential patient cancellations due to illnesses [2][53][59] Efficacy and Safety Data - The sales force is focusing on detailing the efficacy data, particularly the three-year EMBARK data, while addressing safety concerns in context [2][67][70] - Physicians have responded positively to the EMBARK data, finding it consistent with their experiences [2][71][73] Clinical Trials and Data - Enrollment for non-ambulant patients in the Cohort 8 study has begun, with five sites currently open for dosing [2][90][92] - The primary endpoint for the study will focus on the rate of Acute Liver Injury (ALI) [2][96] Competitive Landscape - Sarepta is preparing for competition from a direct competitor, EXONDYS, by emphasizing the long-term efficacy and safety profile of its PMOs [2][246][260] - The company does not anticipate significant flexibility in pricing due to the small patient population [2][247] Future Developments - Sarepta is working on a combination approach using the TRiM platform with PMOs, with updates expected in **2027** [2][288][296] - The company is also developing a proprietary DUX4-related gene knockdown biomarker, with ongoing validation work [2][222][228] Regulatory Engagement - Sarepta plans to meet with the FDA to discuss potential full approval for its products, with a focus on the data supporting their market presence [2][263][271] Conclusion - Sarepta Therapeutics is navigating a complex landscape with its gene therapy products, focusing on expanding its sales force, managing revenue expectations, and preparing for competitive pressures while emphasizing the efficacy and safety of its therapies [1][2][3][4]

Core Insights - CRISPR Therapeutics reported a narrower loss of $1.17 per share for Q3 2025, compared to the Zacks Consensus Estimate of a loss of $1.32, but wider than the loss of $1.01 per share in the same quarter last year [2][8] - Total revenues for the quarter were $0.9 million, significantly missing the Zacks Consensus Estimate of $6.7 million, and up from $0.6 million in the year-ago period [2][8] Financial Performance - The company experienced a 28% year-over-year decline in R&D expenses to $58.9 million, attributed to reduced manufacturing and employee-related costs [9] - General and administrative expenses fell 3% year-over-year to $16.9 million [9] - Net collaboration expenses increased to $57.1 million from $11.2 million in the previous year, primarily due to reaching a deferral limit on costs related to the Casgevy program [9] - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $1.94 billion, up from $1.72 billion as of June 30, 2025 [10] Product Development and Pipeline - CRISPR Therapeutics and Vertex Pharmaceuticals' Casgevy therapy has been approved for sickle cell disease and transfusion-dependent beta thalassemia, with Vertex expecting over $100 million in revenues for Casgevy this year [5][6] - The company completed enrollment for pediatric trials of Casgevy and plans to present initial data at the American Society of Hematology annual meeting on December 6, 2025 [11] - CRISPR is advancing two next-generation CAR-T therapy candidates, CTX112 and CTX131, with updates expected by year-end [12] - The company is also studying in-vivo candidates CTX310 and CTX320, with CTX310 showing significant reductions in ANGPTL3, LDL, and triglyceride levels [13] - A collaboration with Sirius Therapeutics is diversifying the pipeline into RNA therapeutics, with an investigational RNA therapy SRSD107 in mid-stage studies [14] Market Performance - Shares of CRISPR Therapeutics have increased by 39% year-to-date, outperforming the industry growth of 11% [3]